The Effect of Granulocyte Colony Stimulating Factor (GCSF) on Immune Response to Hepatitis B Vaccine in End-Stage Renal Disease (ESRD) Patients Undergoing Hemodialysis

INTERVENTION: Intramuscular injection of double dose of HBV vaccine (40 micro gr) and simultaneous injection of Granolocyte monocyte colony stimulating factor (GM‐CSF) (300 micro gr). 3 doses of HBV vaccine at months 0,1 and 4 will be injected. GM‐CSF will be administered after each injection of HBV vaccine. CONDITION: Immunity against hepatitis B virus PRIMARY OUTCOME: antibody against hepatitis B surface antigen (anti‐HBS antibody) with a titer of 10IU/L or more after blood analysis, ; This was measured by blood sample analysis. ; The titer of anti HBS antibody in blood samples will be examined SECONDARY OUTCOME: None INCLUSION CRITERIA: End stage renal disease (ESRD) patients on hemodialysis